Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has earned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $110.91.

GPCR has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Citigroup reaffirmed a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen cut Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 3rd. Finally, Citizens Jmp restated a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a research note on Wednesday, September 9th.

Structure Therapeutics Trading Up 0.8%

Shares of NASDAQ:GPCR traded up $0.16 during trading on Friday, reaching $20.00. 1,346,219 shares of the company traded hands, compared to its average volume of 985,796. Structure Therapeutics has a 52-week low of $18.70 and a 52-week high of $94.90. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -15.50 and a beta of -1.12. The business’s fifty day moving average is $27.88 and its 200-day moving average is $46.06.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). On average, sell-side analysts predict that Structure Therapeutics will post -2.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Large investors have recently bought and sold shares of the business. Squarepoint Ops LLC increased its position in shares of Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock valued at $6,740,000 after purchasing an additional 102,929 shares during the last quarter. Wellington Management Group LLP raised its holdings in Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock valued at $396,054,000 after buying an additional 119,146 shares during the period. Orbimed Advisors LLC raised its holdings in Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock valued at $71,114,000 after buying an additional 313,600 shares during the period. Handelsbanken Fonder AB bought a new stake in Structure Therapeutics in the second quarter worth $1,041,000. Finally, SEB Asset Management AB bought a new stake in Structure Therapeutics in the first quarter worth $11,811,000. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.